Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H38O7 |
| Molecular Weight | 450.565 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O
InChI
InChIKey=WJHHVCCYLJBCAD-BAHJLIKDSA-N
InChI=1S/C25H38O7/c1-24-9-7-14(27)11-13(24)3-4-15-16-5-6-19(25(16,2)10-8-17(15)24)32-23-22(30)21(29)20(28)18(12-26)31-23/h11,15-23,26,28-30H,3-10,12H2,1-2H3/t15-,16-,17-,18+,19-,20+,21-,22+,23-,24-,25-/m0/s1
Testosterone glucoside is a conjugated form of steroid testosterone investigated at Strakan Ltd (now Kyowa Hakko Kirin Co. Ltd). Testosterone glucoside is bioavailable when given orally, as well as intramuscularly, and is readily metabolised to testosterone. It had been in Phase II study for the treatment of hypogonadism, however development was discontinued.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
51587-38-3
Created by
admin on Wed Apr 02 19:47:48 GMT 2025 , Edited by admin on Wed Apr 02 19:47:48 GMT 2025
|
PRIMARY | |||
|
558BM62QQ3
Created by
admin on Wed Apr 02 19:47:48 GMT 2025 , Edited by admin on Wed Apr 02 19:47:48 GMT 2025
|
PRIMARY | |||
|
9846597
Created by
admin on Wed Apr 02 19:47:48 GMT 2025 , Edited by admin on Wed Apr 02 19:47:48 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
